|Bid||15.09 x 34100|
|Ask||16.77 x 800|
|Day's Range||15.37 - 16.06|
|52 Week Range||5.27 - 17.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.87|
WASHINGTON/NEW YORK, Aug 16 (Reuters) - The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis. In a statement, the U.S. Justice Department and Drug Enforcement Administration (DEA) said the proposed cut would be in keeping with President Donald Trump's effort to cut opioid prescription fills by one-third within three years. Trump on Thursday also pressed U.S. Attorney General Jeff Sessions to sue drug manufacturers over the opioid crisis.
DUBLIN , Aug. 15, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that it is lifting a temporary stay of its litigation against the U.S. Food and Drug Administration (FDA). ...
RBC Is Bullish on Generic Pharma: Upgrades MYL, AMRX, ENDO, AKRXRBC updates its view on the generic pharma industry
In its Q2 2018 earnings conference call, Endo International (ENDP) raised its 2018 adjusted EBITDA guidance from $1.2 billion–$1.3 billion to $1.27 billion–$1.33 billion. It expects its adjusted gross margin to be 68.5%–69.5%, which is higher than its previously projected range of 67%–68%. Wall Street analysts have projected Endo International’s 2018 adjusted diluted EPS at $2.50, which would be a YoY decline of 34.4%.
The golfer and pharmaceuticals company are working together to educate people about Dupuytren's Contracture.
In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY (year-over-year) decline of 18.4%. Additionally, the discontinuation of commercialization of certain generic pharmaceutical products in the US market, competitive pressures, and the divestitures of Grupo Farmacéutico Somar and Litha Healthcare Group had negative impacts on Q2 revenues. To know more about the performance of Endo International stock after its Q2 2018 earnings release, be sure to read Why Endo International Stock Soared after Q2 Results.
Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 8) AstraZeneca plc (ADR) (NYSE: AZN ) Bio-Rad Laboratories, Inc. ...
DUBLIN and MALVERN, Pa., Aug. 9, 2018 /PRNewswire/ -- Fresh off a successful summer of tournament play, four-time PGA TOUR winner Tim Herron is once again teaming up with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP), on Facts on Hand, an educational campaign to raise awareness of Dupuytren's Contracture, a common yet often misunderstood hand condition. For the campaign's second year, Herron is bringing an interactive experience to three PGA TOUR tournaments to illustrate the challenges he has faced as a professional golfer living with Dupuytren's Contracture.
Endo International (ENDP) was trading at $16.63 today, which is a ~31.46% rise from yesterday’s close of $12.65. The stock started rising after Endo International released its second-quarter 2018 financial results and hit a 52-week high of $17.34. Yesterday, Endo International stock closed at $12.65, which represents ~140% growth from its 52-week low of $5.27 on April 4, 2018.
On August 7, Mallinckrodt (MNK) reported revenues of ~$631.7 million for the second quarter, which is ~5.3% growth YoY (year-over-year) on a reported basis and 5.0% on a constant currency basis. The company reported non-GAAP EPS of $1.78, which is a rise of 30.9% YoY. The company beat Wall Street analysts’ revenue and non-GAAP EPS estimates for the second quarter by $11.31 million and $0.30, respectively.
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Endo (ENDP) delivered earnings and revenue surprises of 38.18% and 4.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Dublin-based company said it had a loss of 27 cents per share. Earnings, adjusted for one-time gains and costs, were 76 cents per share. The results surpassed Wall Street expectations. The average ...
MARKET PULSE Endo International PLC (ENDP) shares rose 16.3% in Wednesday premarket trade after the company reported second-quarter profit and revenue beats and increased 2018 guidance. The company reported a loss of $52.
Nevakar Inc., a specialty pharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it recently entered into an exclusive licensing agreement with Endo International plc’s (ENDP) subsidiary, Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the U.S. and Canada. Pursuant to the agreement, Nevakar will develop and seek U.S. Food and Drug Administration (FDA) approval for these products and Endo’s Par Pharmaceutical Sterile Products division will launch and distribute the products upon approval. “We are pleased to establish this partnership with Endo, a respected pharmaceutical company with a significant and growing presence in sterile and critical care products.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Endo International Plc (NASDAQ: ENDP ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 9:00 AM Eastern Time. ...